Bromantane (Ladasten)

The upside on Bromantane comes from three places. First, the mechanism is genuinely novel: epigenetic activation of dopamine biosynthesis through TH promoter demethylation is rare among nootropics, and the BDNF / NGF arm gives a plausible plasticity rationale beyond raw stimulation. Second, the clinical signal in asthenia is real, with a 728-patient open-label cohort reporting a 90.8% CGI-I responder rate at 50 to 100 mg/day for 28 days. Third, the dual-mechanism profile (psychostimulant pattern in high-baseline-alpha responders, anxiolytic pattern in low-alpha responders, Neznamov 2008) means a meaningful subset of users sees an unusual combination of energy and calm rather than the jittery activation typical of dopaminergics. The boundary condition is that almost all of this evidence sits in a single Russian institutional consortium, which is why no upside dimension scores above 4.0 / 5.0.

Efficacy (3.5/5.0): Voznesenskaia 2010 is the strongest citable finding: 728 outpatients with asthenic syndrome, 50 to 100 mg/day for 28 days, CGI-S responder rate 76.0%, CGI-I responder rate 90.8%, with therapeutic benefit persisting at least one month after discontinuation. The trial was multicenter and used standardized psychiatric outcome scales, which gives the responder numbers more weight than a typical Russian clinical paper, but it was open-label and had no placebo arm, so expectancy and rater bias inflate the effect estimate. The placebo-controlled Neznamov 2009 RCT confirmed superiority over placebo on asthenia symptom load and absence of withdrawal syndrome but the published abstract does not contain the sample size or specific effect-size numbers. Cohen's d is not extractable for any human cognitive endpoint. Animal work-capacity data is consistent and sustained: bromantane at 0.5 to 50 mg/kg increased rodent physical work capacity 1.3 to 1.6 times phenamine with greater than 24-hour duration (Morozov 1998).

Breadth of Benefits (2.5/5.0): Bromantane has documented or plausible activity across three systems. The fatigue and asthenia axis is the strongest with human RCT support (Voznesenskaia 2010, Neznamov 2009). The stress-resilience axis covers heat, hypoxia, carbon monoxide, and combined-stressor protection in animal models (Oliynyk and Oh 2012, Morozov 1999). The cognition axis is mechanism-supported via D1- and D5-dependent hippocampal LTP transformation (Mikhaylova 2007) but lacks dedicated cognitive-battery RCTs in humans. There is no clinically meaningful breadth claim outside neuropsychiatric indications: cardiovascular, metabolic, longevity, and body-composition claims are entirely absent from the literature.

Evidence Quality (2.0/5.0): Without the integrity adjustment, the evidence base would land around 2.5 to 3.0 (one Phase III multicenter trial plus one placebo-controlled RCT plus roughly 30 mechanistic preclinical papers, all from a single Russian institutional consortium). A 1.0-point downward adjustment for industry funding combined with two industrial actors walking away brings the dimension to 2.0. Pharmstandard discontinued the Russian Ladasten manufacturing in 2018 and allowed the registration to lapse, and Algernon Pharmaceuticals retired the NP-160 program after announcing but never peer-reviewing positive 2019 NASH and CKD preclinical data. Two industrial actors walking away in two countries is structurally weaker than a compound that has simply not yet been picked up by Western developers. Zero Cochrane reviews, zero ClinicalTrials.gov registrations, zero NIH-funded studies. The closest Western touchpoint is the Oliynyk and Oh 2012 Korean narrative review, which is not a systematic review or meta-analysis.

Speed of Onset (3.5/5.0): Subjective stimulation typically begins 1.5 to 2 hours after an oral dose with a plasma half-life around 11.2 hours and Tmax of 2.75 hours in women and 4 hours in men (Oliynyk and Oh 2012). The Russian Ladasten label cites a therapeutic effect within 1 to 3 days. Full asthenic relief in trials manifested over 1 to 2 weeks (Voznesenskaia 2010 had endpoint readings at days 3, 7, 14, and 28). Onset is slower than Modafinil (under one hour) but faster than SSRI antidepressants. Bioavailability is approximately 42% oral.

Durability (3.5/5.0): Therapeutic benefit persisted at least one month after discontinuation in the Voznesenskaia 2010 cohort, which is unusual for a stimulant and consistent with a gene-induction mechanism that outlasts plasma drug exposure. A 2-month rat course showed no tolerance and full recovery within 2 months post-discontinuation (Iezhitsa 2000), the longest published animal course in the Bromantane literature. Anecdotal forum reports document tolerance after 6 weeks of continuous use in some users, which is why the community standard is 4 weeks on followed by 4 to 8 weeks off. No published cycling RCT exists.

Bioindividuality Upside (4.0/5.0): Bromantane shows unusually high bioindividuality. Neznamov 2008 stratified neurasthenia patients by baseline EEG and observed a psychostimulant-shaped EEG (alpha-frequency increase) in high-baseline-alpha patients and an anxiolytic-shaped EEG (low-frequency alpha increase) in low-alpha patients, which means the same dose produces different drug profiles depending on baseline cortical state. Pharmacokinetic sex differences (women: Tmax 2.75 h, lower half-life; men: Tmax 4 h) are documented and unusual. Forum reports cluster around a 25 to 30% null-response cohort, which may partially reflect counterfeit research-chemical sourcing rather than true non-response, but a meaningful low-dose responder cohort is also documented (effective response at 30 mg with the effect profile shifting at 100 mg). DAT, COMT, and BDNF polymorphism effects are theoretically plausible but unstudied.